TCGX led a $135m Series B round in Adcendo.

TCGX, a healthcare investment firm, led a $135m Series B round in Adcendo, a biotech company focused on the development of first-in-class ADCs for the treatment of cancers, with participation from TPG, Orbimed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital, Logos Capital, RA Capital Management, Novo Holdings, Pontifax Venture Capital, Dawn Biopharma, HealthCap, Gilde Healthcare and Ysios Capital. “We are thrilled with a financing round of this magnitude and the support shown from such a strong group of investors as we continue to advance our pipeline of breakthrough ADCs for the treatment of underserved cancers. The excitement in the ADC space paired with our team’s experience and passion for the underlying science motivates us to continue pushing our programs forward into the clinic. We look forward to achieving key milestones across our pipeline with the support of this fundraising,” Michael Pehl, Adcendo CEO.